Adalimumab (Humira), an anti-tumor necrosis factor α (TNFα) antibody, is a completely human mAb approved by the FDA in 2002 for the treatment of cancer and autoimmunity [34,35,36,37,38]. The gene discussed is TNF; the disease is cancer.